Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12932836 | 0.83 | CCR2 (0.32) | CCR2 | |
| SCHEMBL13396225 | 0.83 | CCR2 (0.32) | CCR2 | |
| SCHEMBL19967708 | 0.79 | — | — | |
| SCHEMBL15625886 | 0.77 | — | — | |
| SCHEMBL12053826 | 0.77 | BIRC2 (0.34) | CCR2 | |
| SCHEMBL12053823 | 0.77 | BIRC2 (0.34) | CCR2 | |
| SCHEMBL19365994 | 0.77 | — | — | |
| SCHEMBL731706 | 0.77 | BIRC2 (0.34) | CCR2 | |
| SCHEMBL13859624 | 0.76 | — | — | |
| SCHEMBL22023628 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043621-B2 | Small molecule inhibitors of Interleukin-4 | TRUSTEES OF BOSTON UNIVERSITY (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043621-B2 | Small molecule inhibitors of Interleukin-4 | TRUSTEES OF BOSTON UNIVERSITY (US) | 2024-07-23 | — | — | US | disclosed |
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230057177-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2023-02-23 | — | — | US | disclosed |
| US-20220152215-A1 | Immunoconjugates Targeting CEA | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-20220143012-A1 | Macromolecule-Supported TLR Agonists | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-05-12 | — | — | US | disclosed |
| US-20210395244-A1 | MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MEK) DEGRADATION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2021-12-23 | — | — | US | disclosed |
| US-20210317114-A1 | SMALL MOLECULE INHIBITORS OF INTERLEUKIN-4 | TRUSTEES OF BOSTON UNIVERSITY (US) | 2021-10-14 | — | — | US | disclosed |
| US-20210154316-A1 | Immunoconjugates | BOLT BIOTHERAPEUTICS, INC. (US) | 2021-05-27 | — | — | US | disclosed |
| US-20200140556-A1 | Methods and Compositions for Dectin-2 Stimulation and Cancer Immunotherapy | HOWARD HUGHES MEDICAL INSTITUTE | 2020-05-07 | — | — | US | disclosed |
| US-20180072666-A1 | ENOYL REDUCTASE INHIBITORS WITH ANTIBACTERIAL ACTIVITY | NOVALEX THERAPEUTICS INC (US) | 2018-03-15 | — | — | US | disclosed |
| US-8658650-B2 | Substituted 1,1,3,1-tetraoxidobenzo[D][1,3,2]dithiazoles as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY | 2014-02-25 | — | — | US | disclosed |
| US-20110319429-A1 | SUBSTITUTED 1,1,3,1-TETRAOXIDOBENZO[D][1,3,2]DITHIAZOLES AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, ERBB2, NTRK1 | CCR2 3099/4885 |
| US-20210154316-A1 | Immunoconjugates | FCGR3B, FCGR2A, FCGR1A | CCR2 180/4885 |
| US-20110319429-A1 | SUBSTITUTED 1,1,3,1-TETRAOXIDOBENZO[D][1,3,2]DITHIAZOLES AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | GRM1, GRM4, GRIK4 | CCR2 2100/4885 |
| US-20210395244-A1 | MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MEK) DEGRADATION COMPOUNDS AND METHODS OF USE | MAP2K2, MAP2K1, MAP2K7 | CCR2 2362/4885 |
| US-20200140556-A1 | Methods and Compositions for Dectin-2 Stimulation and Cancer Immunotherapy | TLR2, TLR8, TLR3 | CCR2 221/4885 |
| US-12043621-B2 | Small molecule inhibitors of Interleukin-4 | IL4, IL2, IL4I1 | CCR2 296/4885 |
| US-20180072666-A1 | ENOYL REDUCTASE INHIBITORS WITH ANTIBACTERIAL ACTIVITY | FAR1, TECR, ECI1 | CCR2 4194/4885 |
| US-20210317114-A1 | SMALL MOLECULE INHIBITORS OF INTERLEUKIN-4 | IL4, IL2, IL4I1 | CCR2 296/4885 |
| US-20220152215-A1 | Immunoconjugates Targeting CEA | CD47, FCGR3B, FCGR1A | CCR2 134/4885 |
| US-20230057177-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, MDM2 | CCR2 3044/4885 |
| US-20220143012-A1 | Macromolecule-Supported TLR Agonists | TLR8, TLR7, TLR9 | CCR2 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.